Sign In
Buy BCLI
$0.770
-0.0217 (-2.74%)
At Close: Jun 03, 2026
Team Gleason is collaborating with Boston Children’s Hospital’s ALS Augmentative Communication Program to provide voice banking and message banking.
16,310 Shares in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) Acquired by American International Group Inc.
04:46am, Thursday, 24'th Sep 2020
American International Group Inc. purchased a new position in Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) during the 2nd quarter, HoldingsChannel reports. The firm purchased 16,310 shares of the bi
Food Safety Testing Market by Contaminant, Technology, and Food Tested - Global Forecast to 2027 - ResearchAndMarkets.com
12:00am, Wednesday, 16'th Sep 2020
The
Everbridge, Inc. (NASDAQ: EVBG), der weltweit führende Anbieter im Bereich Critical Event Management (CEM), teilte heute mit, dass das Programm des vi
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the publication of a manuscript titled, "Effects of M
Arizona Metals Corp. (TSX.V:AMC, OTCQB:AZMCF) (the “Company” or “Arizona Metals”) is pleased to announce the first drill hole from its recently comple
We're Keeping An Eye On Brainstorm Cell Therapeutics' (NASDAQ:BCLI) Cash Burn Rate
01:03pm, Monday, 10'th Aug 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
BrainStorm to Present at the 40th Annual Canaccord Genuity Growth Conference
11:30am, Monday, 10'th Aug 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced Ralph Kern, MD, MHSc, President and Chief Medical Off
Evogene Ltd. (EVGN) CEO Ofer Haviv on Q2 2020 Results - Earnings Call Transcript
04:25am, Monday, 10'th Aug 2020
Evogene Ltd. (NASDAQ:EVGN) Q2 2020 Earnings Conference Call August 5, 2020 09:00 ET Company Participants Ofer Haviv - Chief Executive Officer Dorit Kreiner - Chief Financial Officer Gadi Ben Nissim -
BCLI: Phase 3 ALS Data Expected by the End of November 2020…
09:50am, Friday, 07'th Aug 2020
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Topline Data from Phase 3 ALS Trial Before End of November 2020 BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) is c
BrainStorm Announces Financial Results for the Second Quarter of 2020 and Provides a Corporate Update
11:00am, Wednesday, 05'th Aug 2020
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today financial results for the second quarter and first half ende
The Daily Biotech Pulse: Novavax Vaccine Data, Aerpio Gets $5.1M Funding For COVID Trial, Rigel Gains Big On Earnings
12:00am, Wednesday, 05'th Aug 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination...
Conformance Technologies Deepens Relationship with InfoSecure Redteam
12:00am, Tuesday, 04'th Aug 2020
InfoSecure Redteam becomes Conformance Cybersecurity to expedite strategic market penetration of products and services via Conformance Technologies.
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
12:00am, Sunday, 02'nd Aug 2020
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update
11:58am, Monday, 27'th Jul 2020
BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company w
